DEVELOPMENT AND EVALUATION OF NANOSPONGES LOADED EXTENDED RELEASE TABLETS OF LANSOPRAZOLE
Universal Journal of Pharmaceutical Research, 2019 Nanosponges are tiny sponges with an average diameter below 1µm and consist of cavities filled with drug molecules. Lansoprazole is one of the classes of proton pump inhibitors, it reduces gastric acidity, and used in disorders such as gastric ulcer ...
D. J. Francis, F. Yusuf
semanticscholar +3 more sources
Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments for Eradication [PDF]
The Korean Journal of Helicobacter and Upper Gastrointestinal ResearchObjectives Tegoprazan, a novel potassium-competitive acid blocker with rapid and effective antisecretory activity, was approved for the treatment of Helicobacter pylori infections in Korea in March 2020.
Seokin Kang +6 more
doaj +3 more sources
Electrochemical behavior of lansoprazole at a multiwalled carbon nanotubes-ionic liquid modified glassy carbon electrode and its electrochemical determination [PDF]
Journal of the Serbian Chemical Society, 2014 The electrochemical behavior of lansoprazole (LNS) has been investigated at a glassy carbon electrode (GCE) and the electrode modified by a gel containing multiwalled carbon nanotubes (MWCNTs) and an room-temperature ionic liquid (RTIL) of 1 ...
Liu Li-Hong +3 more
doaj +3 more sources
The proton-pump inhibitor lansoprazole enhances amyloid beta production.
PLoS ONE, 2013 A key event in the pathogenesis of Alzheimer's disease (AD) is the accumulation of amyloid-β (Aβ) species in the brain, derived from the sequential cleavage of the amyloid precursor protein (APP) by β- and γ-secretases.
Nahuai Badiola +8 more
doaj +3 more sources
A drug–drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics [PDF]
Cancer Chemotherapy and Pharmacology, 2019 Quizartinib, a potent, selective FMS-like tyrosine kinase 3 (FLT3) inhibitor, is currently in phase 3 development for patients with FLT3–internal tandem duplication-mutated acute myeloid leukemia (AML).
Jianke Li +4 more
semanticscholar +2 more sources
Dose and duration shape the efficacy of vonoprazan versus lansoprazole for erosive esophagitis: insights from meta-regression. [PDF]
Therap Adv GastroenterolHuang PF, Chen HW, Liang YJ.
europepmc +2 more sources
Research in Pharmaceutical Sciences, 2018 Lansoprazole is a proton-pump inhibitor that is commonly used to treat many gastric illnesses. However, little is known about its effect on sperm function.
S. Banihani, Falak H Khasawneh
semanticscholar +2 more sources
Pharmacokinetic Profiles of Lansoprazole in Patients With Morbid Obesity Post‐Roux‐en‐Y Gastric Bypass Surgery [PDF]
Clinical and Translational ScienceData on the effects of Roux‐en‐Y gastric bypass (RYGB) surgery on lansoprazole pharmacokinetics in morbidly obese patients are limited. This study aimed to evaluate the impact of RYGB surgery on the pharmacokinetic profile of lansoprazole in Thai ...
Suthep Udomsawaengsup +9 more
doaj +2 more sources
JAMA Network Open, 2023 Key Points Question In adult medical inpatients receiving ceftriaxone treatment, is concomitant lansoprazole compared with other proton pump inhibitors associated with increased risk of ventricular arrhythmia or cardiac arrest and death?
Anthony D. Bai +6 more
semanticscholar +1 more source
Omeprazole and lansoprazole enantiomers induce CYP3A4 in human hepatocytes and cell lines via glucocorticoid receptor and pregnane X receptor axis. [PDF]
PLoS ONE, 2014 Benzimidazole drugs lansoprazole and omeprazole are used for treatment of various gastrointestinal pathologies. Both compounds cause drug-drug interactions because they activate aryl hydrocarbon receptor and induce CYP1A genes.
Aneta Novotna, Zdenek Dvorak
doaj +1 more source